Pharmacoeconomic Considerations in Treating Ovarian Cancer

Author： Bodurka-Bevers D.   Sun C.C.   Gershenson D.M.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.17, Iss.2, 2000-02, pp. : 133-150

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacoeconomic Considerations in Treating Actinic Keratosis

By Neidecker Marjorie V.  

PharmacoEconomics, Vol. 27, Iss. 6, 2009-06 ,pp. : 451-464

Adis International

Access to resources Recommend Favorite

Pharmacoeconomic Considerations in Treating Patients With Acute Leukaemia

By Jønsson V.  

PharmacoEconomics, Vol. 15, Iss. 2, 1999-02 ,pp. : 167-178

Adis International

Access to resources Recommend Favorite

Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease

By Reese Jens P   Dams Judith   Winter Yaroslav   Balzer-Geldsetzer Monika   Oertel Wolfgang H   Dodel Richard  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 7, 2012-05 ,pp. : 939-958

Informa Healthcare

Access to resources Recommend Favorite

Aromatase inhibitors for breast cancer: pharmacoeconomic considerations

By Higa Gerald M  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 6, 2001-06 ,pp. : 987-995

Informa Healthcare

Access to resources Recommend Favorite

Paclitaxel: A Pharmacoeconomic Review of its Use in the Treatment of Ovarian Cancer

By Young M.   Plosker G.L.  

PharmacoEconomics, Vol. 19, Iss. 12, 2001-01 ,pp. : 1227-1259

Adis International

Access to resources Recommend Favorite